达格列净呋喃环杂质的合成

以5-溴-2-氯-4′-乙氧基二苯甲烷为原料，与2,3-二-O-叔丁基二甲基硅基-5,6-O-异亚丙基-D-葡糖醛酸-1,4-内酯缩合后，再经还原、脱保护、酯化及水解反应合成了达格列净呋喃环杂质--(1S)-1,4-脱水-1-(4-氯-3-(4-乙氧基苄基)苯基)-D-葡萄糖，总收率29.0%，纯度98.5%，其结构经¹H NMR，¹³C NMR， DEPT135，¹H-¹H COSY， HSQC， HMBC和MS(ESI)确证。     

新型螺[氧化吲哚-3,3′-吡唑]-5′-二氟甲基-4′-甲酸酯类化合物的合成

以原位生成的二氟甲基重氮甲烷（CF₂HCHN₂）与靛红衍生的3-烯基氧化吲哚为原料,通过[3+2]环加成反应和1,3-H迁移过程,合成了3种结构新型的螺[氧化吲哚 3,3′-吡唑]-5′-二氟甲基-4′-甲酸酯类化合物,收率41~68%, dr 91: 9~99 : 1,其结构经¹H NMR, ¹³C NMR, ¹⁹F NMR和HR-MS(ESI-TOF)表征。并通过单晶X-射线单晶衍射确定其相对构型。     

含嘧啶基团的新型亲水性共轭大环化合物的合成

以三乙甘醇单甲醚为原料,制得化合物1和2; 1和2经取代反应制得1-【2-{1-[2-(2-甲氧基乙氧基)乙氧基]乙氧基}甲基-3-[2-(2-甲氧基乙氧基)乙氧基]乙氧基】丙氧基-3,5-二溴苯(3)和1-[2-(2-甲氧基乙氧基)乙氧基]乙氧基-3,5-二溴苯(4); 3和4分别与双频那醇合二硼反应制得化合物5和6; 6与5-溴-2-碘嘧啶发生Suzuki-Miyaura交叉偶联反应制得化合物7; 5与7在铂催化下发生Suzuki-Miyaura交叉偶联反应合成了一个新型的共轭大环化合物,其结构经¹H NMR, ¹³C NMR和MALDI-TOF-MS表征。     

5-取代-3,4-二卤-2(5H)-呋喃酮的Sonogashira偶联反应

以5-取代-3,4-二卤-2(5H)-呋喃酮为底物进行Sonogashira偶联反应, 考察了反应温度、反应时间、钯催化剂种类与用量、碱种类与用量、溶剂、底物结构等对偶联反应的影响, 合成了28种新的2(5H)-呋喃酮衍生物, 其结构用IR, ¹H NMR, ¹³C NMR, MS和元素分析等方法进行了表征. 在优化的反应条件下, 即反应溶剂为甲苯、催化剂为3 mol% Pd(PPh₃)₄和10 mol% CuI、碱为6 equiv. KF、反应时间72 h、反应温度30 ℃时, 反应产率42%～84%. 利用该Sonogashira偶联反应合成新型的多官能团烯二炔结构化合物, 不仅合成途径简捷、反应条件温和, 绝大部分反应产率中等以上, 而且无需额外加入配体, 适用于芳香的和脂肪的末端炔烃.     

抗过敏药物盐酸松齐拉敏的合成

以2-氨基嘧啶、对甲氧基氯苄和N,N-二甲基-2-氯乙胺为原料,经两步N-烃基化反应合成了抗过敏药物盐酸松齐拉敏,总收率75.1%,其结构经¹H NMR, ¹³C NMR和HR-MS(ESI)确证。     

1,8-二(2-吡咯酰胺)-3,6-二氯咔唑的合成、晶体结构及阴离子识别研究

设计并合成了1,8-二(2-吡咯酰胺)-3,6-二氯咔唑化合物(1), 利用X射线单晶衍射研究了该化合物的固态结构. 利用荧光和紫外-可见光谱技术及¹H NMR滴定法研究了其对阴离子的识别. 研究结果表明, 化合物1对H₂PO₄^-离子有较强的识别能力, 且对H₂PO₄^-离子有明显的荧光增强效应, 可用来识别H₂PO₄^-离子. 同时¹H NMR滴定结果显示, 化合物1在阴离子识别过程中发生了构型转化.     

铑催化的3-乙烯基吲哚与芳基三氮唑交换环合制备3-(2,3-二氢吡咯)吲哚衍生物

发展了一种铑催化的3-乙烯基吲哚与芳基三氮唑的环合反应。通过优化催化剂、反应温度、时间和eq.比等反应条件,最终在氩气保护下,以2.5 mol% Rh₂(OAc)₄为催化剂,1,2-二氯乙烷为溶剂,3-乙烯基吲哚和芳基三氮唑的eq.比为1/2时,60 ℃反应6~12h,一步合成了15个新型的3-(2,3-二氢吡咯)吲哚衍生物（3aa~3al, 3ba~3da）,其结构经¹H NMR,¹³C NMR和HR-MS(ESI)表征。      

新型2-取代氨基-3-氟-4-吡啶氟硼酸钾盐的合成

以2,3-二氟-5-氯吡啶为原料,依次经取代和还原反应制得2-取代氨基-3-氟吡啶化合物(2a~2g); 2a~2g与正丁基锂及硼酸三异丙酯经有机锂化法制得相应的硼酸化合物(3a~3g); 3a~3g分别与氟化氢钾经取代反应合成了7个新型的2-取代氨基-3-氟-4-吡啶氟硼酸钾盐,其结构经¹H NMR, ¹³C NMR, IR, ESI-MS和元素分析表征。     

6-氧-叔丁基二甲基硅基-2,4-二-氧-苯甲酰基-3-氧-对甲氧基苄基-α-D-甘露吡喃糖乙硫苷的合成

以D-甘露糖为原料,通过乙酰化、去乙酰化、苯亚甲基化、硅基化等8步反应合成了6-氧-叔丁基二甲基硅基-2,4-二-氧-苯甲酰基-3-氧-对甲氧基苄基-α-D-甘露吡喃糖乙硫苷,总收率21.7%,其结构经¹H NMR, ¹³C NMR, IR和LC-MS(ESI)确证。     

新型2,5-取代-1,3,4-噻二唑衍生物的合成与杀菌活性

根据活性亚结构拼接原理,以2,2-二氟-1,3-苯并二噁茂为起始原料,合成了9个结构新颖的2,5-取代-1,3,4-噻二唑衍生物（I1~I9）,其结构经¹H NMR, ¹³C NMR, ¹⁹F NMR,MS(EI)和元素分析表征,并对化合物的杀菌活性进行了初步测试。结果表明：在100 mg/L浓度下,化合物I-1和I-5对苹果树腐烂病菌(Valsa mali)的抑制活性超过92%,具有进一步研究的价值。      

99mTcN核标记的新型心肌灌注显像剂的研究

通过配体交换反应制备了[99mTcN(PNP5)(DEDC)]+和[99mTcN(PNP5)(DPODC)]+两种新配合物, 其放化纯度均大于90%. 生物性能研究结果表明: 两种配合物在小鼠心肌中的初始摄取高, 肝、肺等非靶组织清除快, 靶/非靶比高, 有利于早期心肌显像. 其中, [99mTcN(PNP5)(DEDC)]+在小鼠中的性质较优, 且其在狗体内的性质接近99mTc-tetrofosmin, 有望成为一种新型心肌灌注显像剂.     

[99mTcN(PNP5)(NOEt)]+: A novel potential myocardial perfusion imaging agent

Summary The asymmetrical [^99mTcN(PNP5)(NOEt)]⁺heterocomplex containing a terminal technetium-nitrogen multiple bond coordinated to the diphosphine ligand (PNP5) and the dithiocarbamate ligand (NOEt), was prepared through ligand exchange reaction. Its radiochemical purity was over 90% as measured by TLC and HPLC. Biodistribution in mice and SPECT imaging in dog were studied. The results showed that [^99mTcN(PNP5)(NOEt)]⁺ possessed high myocardial uptake and good retention, and high target to non-target ratios, suggesting that it may be a potential myocardial perfusion imaging agent.     

99mTcN(PNP5)(NOEt)]+新型心肌灌注显像剂研究

以氯化亚锡为还原剂,SDH(丁二酰二酰肼)为供氮体,经配体交换反应得到[^99mTcN(PNP5)·(NOEt)]⁺,通过TLC和HPLC分析,其放化纯度大于90%.该标记物是一种体外稳定性良好的阳离子配合物,在小鼠和狗体内的心肌初始摄取量高,滞留好,肝和肺等非靶组织清除快,有利于早期心肌显像,有望成为一种新型的心肌灌注显像剂.     

99mTc-labeling of a dithiocarbamate-DWAY fragment using [99mTcN]2+ core for the preparation of potential 5HT1A receptor imaging agents

1-(2-methoxy phenyl) piperazine fragment of WAY100635 or its phenolic analogue, derived from DWAY is used to design the desired structure of 5HT_1A receptor imaging agents. In this study a DWAY analogue was labeled with ^99mTc-nitrido ([^99mTcN]²⁺) core via dithiocarbamate. 2-(piperazin-1-yl) phenol dithiocarbamate was synthesized by the reaction of 2-(piperazin-1-yl) phenol with an equivalent amount of carbon disulfide in KOH solution then radiolabeled with ^99mTc-nitrido core. The final complex was characterized by HPLC and its radiochemical purity was more than 90 %. In vitro stability studies have shown the complex was stable at least 4 h after labeling at room temperature. The n-octanol/water partition coefficient experiment demonstrated log p = 1.34 for ^99mTcN–OHPP–DTC. Biodistribution results showed that radio tracer had moderate brain uptake (0.39 ± 0.03 %ID/g at 15 min and 0.29 ± 0.02 %ID/g at 120 min) and good retention, suggesting that this complex may lead to a further development of a radiotracer with specific binding to 5-HT_1A receptor.     

一种新型脑灌注显像剂99mTcN-CPDTC的制备及生物分布

目前临床上广泛使用的99mTc脑灌注显像剂是以［99mTcO］3+核为中心核的配合物99mTc-乙撑双半胱氨酸二乙酯(99mTc-ECD)和99mTc-六甲基丙撑二胺肟(99mTc-HMPAO). ［99mTc≡N］2+核由于具有较高的化学稳定性以及用99mTcN核代替99mTcO核后其配合物的生物分布性能发生了较大的改变［1～3］, 因此研究含99mTcN核的配合物成为寻找新型放射性药物的一条有效途径.     

New approach to the chemistry of technetium(V) and rhenium(V) phenylimido complexes: novel [M(NPh)PNP]3+ metal fragments (M = Tc, Re; PNP = aminodiphosphine) suitable for the synthesis of stable mixed-ligand compounds

Ligand-exchange reactions of the aminodiphosphine ligand bis[(2-diphenylphosphino)ethyl]amine hydrochloride (PNHP x HCl) with labile M(NPh)Cl3(PPh3)2 precursors (M = Re, Tc) in the presence of triethylamine yield monocationic phenylimido mer,cis-[M(NPh)Cl2(PNHP)]Cl (M = Re, 1; Tc, 2) intermediate complexes. X-ray analyses show that in both compounds the aminodiphosphine acts as a tridentate ligand dictating a mer,cis arrangement. Two chloride ligands, respectively in an equatorial and in the axial position trans to the linear M-NPh moiety, fill the remaining positions in a distorted-octahedral geometry. The chloride trans to the metal-imido core is labile, and is replaced by an alcoholate group, without affecting the original geometry, as established in mer,cis-[Re(NPh)(OEt)Cl(PNHP)]Cl 4. Otherwise, ligand-exchange reactions involving the aminodiphosphine bis[(2-diphenylphosphino)ethyl]methylamine (PNMeP), in which the central secondary amine has been replaced by a tertiary amine function, or its hydrochloride salt (PNMeP x HCl) give rise to three different species, depending on the experimental conditions: fac,cis-[Re(NPh)Cl2(PNMeP)]Cl 3a, cis,fac-Re(NPh)Cl3(PNMeP) x HCl 3b, and mer,trans-[Re(NPh)Cl2(PNMeP)]Cl 3c, which are characterized in solution by multinuclear NMR studies. The monodentate groups incorporated in these intermediate compounds, either halides and/or ethoxide, undergo substitution reactions with bidentate donor ligands such as catechol, ethylene glycol, and 1,2-aminophenol to afford stable mixed ligand complexes of the type [M(NPh)(O,O-cat)(PNP)]Cl [PNP = PNHP M = Re 5, Tc 6; PNP = PNMeP M = Re 7], [Re(NPh)(O,O-gly)(PNP)]Cl [PNP = PNHP 8, PNMeP 9] and [Re(NPh)(O,N-ap)(PNMeP)]Cl 10. X-ray diffraction analyses of the representative compounds 5 and 8 reveal that the aminodiphosphine switches from the meridional to the facial coordination mode placing the heteroatom of the diphosphine trans to the phenylimido unit and the bidentate ligand in the equatorial plane. Solution-state NMR studies suggest an analogous geometry for 6, 7, 9, and 10. Comparison with similar mixed ligand complexes including the terminal nitrido group is discussed.     

Synthesis and biological evaluation of novel 99mTc-oxo and 99mTc-nitrido complexes with phenylalanine dithiocarbamate for tumor imaging

In this study, phenylalanine dithiocarbamate (PHEDTC) ligand was successfully synthesized and then radiolabeled with [^99mTcO]³⁺ core and [^99mTc≡N]²⁺ core to produce ^99mTcO–PHEDTC and ^99mTcN–PHEDTC, respectively. Both complexes were prepared with high radiochemical purity and had good stability. The partition coefficient results showed they were hydrophilic, while ^99mTcN–PHEDTC was more hydrophilic than ^99mTcO–PHEDTC. The biodistribution study in mice bearing S 180 tumor showed that ^99mTcO–PHEDTC and ^99mTcN–PHEDTC had high tumor uptake at 2 h post-injection, 1.91 and 1.21, respectively. The good uptake and retention in tumor together with favorable tumor-to-muscle ratios make them promising candidates for further evaluation as potential tumor imaging agents.     

Synthesis and biodistribution of a novel <Superscript>99m</Superscript>Tc nitrido dithiocarbamate complex containing ether group as a potential myocardial and brain imaging agent

In the present study, a novel ^99mTc nitrido dithiocarbamate complex containing ether group, the bis(2-ethoxyethyl dithiocarbamato) nitrido ^99mTc complex ^99mTcN(EOEDTC)₂ has been synthesized by the reduction of ^99mTcO₄ ⁻ into [^99mTcN]²⁺ with stannous chloride in the presence of succinic dihydrazide and propylenediamine tetraacetic acid, followed by the addition of the corresponding dithiocarbamate ligand. The radiochemical purity of the complex was over 90% as measured by thin layer chromatography (TLC). In vitro studies showed that the complex possessed good stability. Its partition coefficient indicated that it was lipophilic complex. The electrophoresis results showed the complex was neutral. Biodistribution in mice showed that the complex accumulated in the heart and brain with high initial uptake, suggesting the complex may lead to a further development of the radiopharmaceutical as a heart and brain perfusion tracer.     

一种制备盐酸西那卡塞的新方法

（R）-1-萘乙胺与丙烯酰氯发生亲核取代反应制得酰胺（2）; 2与3-三氟甲基碘苯经Heck偶联反应制得α,β-不饱和酰胺（3）; 3经两次还原反应后再与盐酸成盐合成了盐酸西那卡塞,总收率40%,纯度>99.5%, ee值>99.9%,其结构经¹H NMR和¹³C NMR确证。     

Triphenyl phosphine adducts of platinum(IV) and palladium(II) dithiocarbamates complexes: a spectral and in vitro study

Triphenyl phosphine adducts of dithiocarbamate complexes of platinum(IV) and palladium(II) of the type [Pt(L)2PPh3Cl2] and [Pd(L)2PPh3] [L: morpholine dithiocarbamate (L1), aniline dithiocarbamate (L2) and N-(methyl, cyclohexyl) dithiocarbamate (L3)] were prepared and characterized by elemental analysis, electronic, IR, 1H NMR and 13C NMR spectral studies. Thermal studies of the complexes were carried out. In vitro antitumor activity has been screened towards human adenocarcinoma cell lines and showed significant inhibition even at very low concentration.